Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 1.04 LCr |
| Price/Earnings (Trailing) | 18.56 |
| Price/Sales (Trailing) | 2.87 |
| EV/EBITDA | 11.3 |
| Price/Free Cashflow | 54.7 |
| MarketCap/EBT | 14.42 |
| Enterprise Value | 1.07 LCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 1.9% |
| Price Change 1M | -0.10% |
| Price Change 6M | 2.5% |
| Price Change 1Y | 0.40% |
| 3Y Cumulative Return | 11.8% |
| 5Y Cumulative Return | 5.3% |
| 7Y Cumulative Return | 12.2% |
| 10Y Cumulative Return | 7.7% |
| Revenue (TTM) |
| 36.09 kCr |
| Rev. Growth (Yr) | 5.8% |
| Earnings (TTM) | 5.52 kCr |
| Earnings Growth (Yr) | -15.3% |
Profitability | |
|---|---|
| Operating Margin | 20% |
| EBT Margin | 20% |
| Return on Equity | 15.18% |
| Return on Assets | 10.16% |
| Free Cashflow Yield | 1.83% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | -5.1 kCr |
| Cash Flow from Operations (TTM) | 4.64 kCr |
| Cash Flow from Financing (TTM) | 1.19 kCr |
| Cash & Equivalents | 990.6 Cr |
| Free Cash Flow (TTM) | 1.89 kCr |
| Free Cash Flow/Share (TTM) | 22.67 |
Balance Sheet | |
|---|---|
| Total Assets | 54.37 kCr |
| Total Liabilities | 18 kCr |
| Shareholder Equity | 36.37 kCr |
| Current Assets | 27.96 kCr |
| Current Liabilities | 15.1 kCr |
| Net PPE | 9.12 kCr |
| Inventory | 7.58 kCr |
| Goodwill | 1.4 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.08 |
| Debt/Equity | 0.12 |
| Interest Coverage | 20.53 |
| Interest/Cashflow Ops | 16.17 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 8 |
| Dividend Yield | 0.65% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.20% |
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 15% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 44.9% growth over past three years, the company is going strong.
No major cons observed.
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Profitability: Recent profitability of 15% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 44.9% growth over past three years, the company is going strong.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.65% |
| Dividend/Share (TTM) | 8 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 66.87 |
Financial Health | |
|---|---|
| Current Ratio | 1.85 |
| Debt/Equity | 0.12 |
Technical Indicators | |
|---|---|
| RSI (14d) | 63.52 |
| RSI (5d) | 61.36 |
| RSI (21d) | 49.79 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 6, 2025
Dr. Reddy’s Laboratories is set to launch Beyfortus, a novel RSV drug for infants, expanding its immunization portfolio.
The drug Beyfortus, containing the monoclonal antibody nirsevimab, has been approved for use in multiple countries globally.
This collaboration with Sanofi marks a significant advancement in protecting children from the RSV disease burden in India.
Summary of Dr. Reddy's Lab's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Dr. Reddy's Lab ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| LIFE INSURANCE CORPORATION OF INDIA P & GS FUND | 11.79% |
| GVP Family Trust | 11.51% |
| J P Morgan Chase Bank NA | 10.87% |
| VSD Family Trust | 9.06% |
| ICICI PRUDENTIAL VALUE DISCOVERY FUND | 4.56% |
| KALLAM SATISH REDDY HUF | 3.31% |
| NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 |
Detailed comparison of Dr. Reddy's Lab against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.07 LCr | 58.94 kCr | -4.90% | -2.70% | 37.25 | 6.9 | - | - |
| DIVISLAB | Divi's Lab | 1.6 LCr |
Comprehensive comparison against sector averages
DRREDDY metrics compared to Pharmaceuticals
| Category | DRREDDY | Pharmaceuticals |
|---|---|---|
| PE | 18.56 | 33.53 |
| PS | 2.87 | 4.65 |
| Growth | 12.5 % | 9.1 % |
Dr. Reddy's Laboratories Ltd. is a prominent pharmaceutical company with its stock ticker known as DRREDDY. It boasts a substantial market capitalization of Rs. 100,022.4 Crores and is headquartered in Hyderabad, India.
The company operates globally through various segments:
Global Generics: This segment focuses on manufacturing and marketing both prescription and over-the-counter pharmaceutical products, including branded and generic finished dosages. It also has a presence in the biologics business.
Pharmaceutical Services and Active Ingredients (PSAI): Dr. Reddy's manufactures and markets active pharmaceutical ingredients (APIs) and intermediates that serve as crucial components for finished pharmaceutical products. This segment also provides contract research services and manufactures steroids according to customer specifications.
Others: This sector is dedicated to developing therapies in oncology and inflammation, engaging in R&D for differentiated formulations, and offering digital healthcare and IT-enabled business support services.
The company’s product offerings cover a wide range of therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.
Founded in 1984, Dr. Reddy's Lab has generated a trailing 12-month revenue of Rs. 32,071.7 Crores, demonstrating significant financial growth with a revenue increase of 50.6% over the past three years. The company is profitable, having achieved a profit of Rs. 5,448.3 Crores in the past four quarters.
Investors are rewarded with dividends, yielding 0.6% annually, with the last distribution being Rs. 8 per share. However, it is notable that the company has diluted its shareholders' stake by 0.3% in the past three years.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
DRREDDY vs Pharmaceuticals (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
| 2.44% |
| GUNUPATI VENKATESWARA PRASAD HUF | 1.52% |
| SATISH REDDY KALLAM | 1.21% |
| ANURADHA GUNUPATI | 0.01% |
| G V PRASAD | 0% |
| K SHRAVYA REDDY | 0% |
| K VISHAL REDDY | 0% |
| VSD Holdings & Advisory LLP | 0% |
| APS Trust | 0% |
| SKR Family Trust | 0% |
| KVR Family Trust | 0% |
| Serendipity Family Trust | 0% |
| Malli G Family Trust | 0% |
| SRG Family Trust | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 10.46 kCr |
| -9.30% |
| -1.60% |
| 64.37 |
| 15.29 |
| - |
| - |
| CIPLA | Cipla | 1.07 LCr | 29.37 kCr | -9.40% | -9.60% | 23.62 | 3.66 | - | - |
| LUPIN | Lupin | 99.29 kCr | 25.03 kCr | -1.80% | -0.50% | 22.94 | 3.97 | - | - |
| AUROPHARMA | Aurobindo Pharma | 69.17 kCr | 33.03 kCr | -3.60% | -0.10% | 20.21 | 2.09 | - | - |
Analyst / Investor Meet • 02 Feb 2026 Schedule of Analyst meet |
Analyst / Investor Meet • 27 Jan 2026 Transcript of earnings call conducted on January 21, 2026 |
General • 24 Jan 2026 Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 |
Newspaper Publication • 22 Jan 2026 Copies of newspaper publication |
Analyst / Investor Meet • 21 Jan 2026 Earnings call recording |
Investor Presentation • 21 Jan 2026 Copy of Investor Presentation |
Press Release / Media Release • 14 Jan 2026 Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 |
| 0.9% |
| 7,481 |
| 7,414 |
| 6,958 |
| 7,051 |
| 6,661 |
| 6,434 |
| Profit Before exceptional items and Tax | -11.3% | 1,541 | 1,738 | 1,905 | 2,000 | 1,870 | 1,911 |
| Total profit before tax | -11.3% | 1,541 | 1,738 | 1,905 | 2,000 | 1,870 | 1,911 |
| Current tax | 12% | 207 | 185 | 1,026 | 432 | 533 | 771 |
| Deferred tax | -34.7% | 146 | 223 | -531 | -13.8 | -62.9 | -195.8 |
| Total tax | -13.3% | 354 | 408 | 495 | 418 | 470 | 576 |
| Total profit (loss) for period | -11% | 1,190 | 1,337 | 1,410 | 1,587 | 1,404 | 1,342 |
| Other comp. income net of taxes | 58.6% | 177 | 112 | 205 | 109 | -202.4 | 296 |
| Total Comprehensive Income | -5.7% | 1,367 | 1,449 | 1,615 | 1,696 | 1,202 | 1,638 |
| Earnings Per Share, Basic | -10.9% | 14.53 | 16.18 | 17.04 | 19.12 | 16.97 | 3.016 |
| Earnings Per Share, Diluted | -10.9% | 14.52 | 16.17 | 17.02 | 19.1 | 16.94 | 3.01 |
| 6.5% |
| 3,288 |
| 3,086 |
| 2,833 |
| 2,435 |
| 2,270 |
| 2,030 |
| Finance costs | 419% | 110 | 22 | 17 | 38 | 47 | 48 |
| Depreciation and Amortization | 6.5% | 1,039 | 976 | 923 | 814 | 835 | 789 |
| Other expenses | 17.5% | 6,380 | 5,432 | 4,845 | 4,331 | 3,819 | 3,377 |
| Total Expenses | 16% | 16,883 | 14,555 | 13,688 | 12,663 | 11,094 | 9,818 |
| Profit Before exceptional items and Tax | 25% | 7,236 | 5,791 | 3,866 | 2,224 | 3,056 | 2,776 |
| Total profit before tax | 25% | 7,236 | 5,791 | 3,866 | 2,224 | 3,056 | 2,776 |
| Current tax | 31.4% | 1,790 | 1,362 | 864 | 393 | 540 | 484 |
| Deferred tax | 9.2% | 96 | 88 | 389 | 208 | 330 | -645.8 |
| Total tax | 30.2% | 1,886 | 1,449 | 1,253 | 601 | 870 | -161.9 |
| Total profit (loss) for period | 23.2% | 5,349 | 4,342 | 2,613 | 1,623 | 2,186 | 2,938 |
| Other comp. income net of taxes | 126.8% | 9.8 | -31.8 | -53.4 | 51 | 54 | -43.6 |
| Total Comprehensive Income | 24.3% | 5,359 | 4,310 | 2,559 | 1,674 | 2,240 | 2,894 |
| Earnings Per Share, Basic | 23.5% | 64.22 | 52.19 | 31.474 | 19.57 | 26.368 | 35.446 |
| Earnings Per Share, Diluted | 23.6% | 64.13 | 52.092 | 31.406 | 19.516 | 26.292 | 35.376 |
| -20.9% |
| 1,706 |
| 2,156 |
| 1,575 |
| 1,172 |
| 1,048 |
| 899 |
| Goodwill | 0% | 85 | 85 | 85 | 85 | 85 | 85 |
| Non-current investments | 8.1% | 11,146 | 10,310 | 9,969 | 3,203 | 3,303 | 3,142 |
| Loans, non-current | 0% | 1.4 | 1.4 | 1.5 | 62 | 61 | 1.1 |
| Total non-current financial assets | 2.2% | 11,413 | 11,168 | 10,057 | 3,356 | 3,418 | 3,197 |
| Total non-current assets | 6.5% | 23,200 | 21,788 | 19,714 | 12,543 | 11,806 | 11,332 |
| Total assets | 11.2% | 42,591 | 38,291 | 36,660 | 30,359 | 27,986 | 25,375 |
| Borrowings, non-current | - | 0 | 0 | 0 | 0 | 44 | 29 |
| Total non-current financial liabilities | 242.7% | 258 | 76 | 48 | 50 | 44 | 29 |
| Provisions, non-current | 150% | 12 | 5.4 | 9.2 | 9.3 | 7.9 | 7.9 |
| Total non-current liabilities | 26.8% | 991 | 782 | 653 | 580 | 567 | 461 |
| Borrowings, current | 8.2% | 3,663 | 3,386 | 3,710 | 710 | 36 | 22 |
| Total current financial liabilities | 14.4% | 8,618 | 7,532 | 7,841 | 4,520 | 3,649 | 3,337 |
| Provisions, current | -17.1% | 282 | 340 | 298 | 328 | 298 | 305 |
| Current tax liabilities | 538.5% | 499 | 79 | 407 | 67 | 179 | 0 |
| Total current liabilities | 16.6% | 10,087 | 8,652 | 9,099 | 5,538 | 4,701 | 4,440 |
| Total liabilities | 17.4% | 11,078 | 9,434 | 9,752 | 6,118 | 5,268 | 4,901 |
| Equity share capital | 1.2% | 84 | 83 | 83 | 83 | 83 | 83 |
| Total equity | 9.2% | 31,513 | 28,857 | 26,908 | 24,241 | 22,718 | 20,474 |
| Total equity and liabilities | 11.2% | 42,591 | 38,291 | 36,660 | 30,359 | 27,986 | 25,375 |
| 38 |
| 35 |
| 32 |
| 59 |
| - |
| - |
| Net Cashflows from Operations | 21.9% | 5,811 | 4,769 | 5,836 | 1,828 | - | - |
| Income taxes paid (refund) | 20.2% | 1,586 | 1,320 | 783 | 489 | - | - |
| Net Cashflows From Operating Activities | 22.5% | 4,225 | 3,450 | 5,053 | 1,339 | - | - |
| Cashflows used in obtaining control of subsidiaries | 8448.1% | 6,754 | 80 | 46 | 0 | - | - |
| Proceeds from sales of PPE | - | 32 | 0 | 25 | 9.4 | - | - |
| Purchase of property, plant and equipment | 71.9% | 2,339 | 1,361 | 1,000 | 1,311 | - | - |
| Proceeds from sales of investment property | -101.1% | 0 | 88 | 0 | 0 | - | - |
| Proceeds from sales of intangible assets | - | 10 | 0 | 0 | 0 | - | - |
| Purchase of intangible assets | -41.1% | 137 | 232 | 571 | 54 | - | - |
| Dividends received | -102.3% | 0 | 45 | 0 | 0 | - | - |
| Interest received | 120.4% | 400 | 182 | 100 | 157 | - | - |
| Other inflows (outflows) of cash | 195.8% | 60 | -60.6 | 0 | 0 | - | - |
| Net Cashflows From Investing Activities | -66.1% | -5,697.6 | -3,430.3 | -3,447.6 | -2,038 | - | - |
| Proceeds from issuing shares | -77.2% | 19 | 80 | 16 | 33 | - | - |
| Payments to acquire or redeem entity's shares | - | 139 | 0 | 0 | 0 | - | - |
| Proceeds from borrowings | 264.8% | 2,584 | 709 | 0 | 968 | - | - |
| Repayments of borrowings | - | 0 | 0 | 2,170 | 0 | - | - |
| Payments of lease liabilities | - | 28 | 0 | 20 | 17 | - | - |
| Dividends paid | 0.2% | 666 | 665 | 498 | 415 | - | - |
| Interest paid | 456.2% | 179 | 33 | 46 | 64 | - | - |
| Other inflows (outflows) of cash | - | 0 | 0 | 21 | 0 | - | - |
| Net Cashflows from Financing Activities | 2273.1% | 1,591 | 68 | -2,696.9 | 506 | - | - |
| Effect of exchange rate on cash eq. | -233.3% | 0.2 | 1.6 | 44 | 48 | - | - |
| Net change in cash and cash eq. | 33% | 118 | 89 | -1,047.2 | -145.9 | - | - |
Analysis of Dr. Reddy's Lab's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| a) Global Generics | 89.4% | 8 kCr |
| b) Pharmaceutical Services and Active Ingredients | 10.6% | 947.2 Cr |
| Total | 8.9 kCr |